35.4 F
New York
Friday, February 26, 2021

Kazia Therapeutics’ [NASDAQ: KZIA] Paxalisib Receives Orphan Drug Designation

Must read

MongoDB [NASDAQ: MDB] Announces Extended 5-year Collaboration With Google Cloud

MongoDB Inc. , reported an extended five-year collaboration that will stretch out their current go-to-market relationship. Moreover, it will provide a more profound integration...

Humana Inc [NYSE: HUM] Announces Collaboration With Mercy

Mercy and  Humana Inc. announces that the companies have collaborated. Both the companies inked a contract to extend patient access to virtual healthcare...

International Paper [NYSE: IP] Reports Purchase Of Berkley MF LLC

International Paper has purchased Berkley International's Molded Fiber (Pulp) production subsidiary, Berkley MF LLC. Berkley is the provider of essential packaging and e-commerce...

Perspecta [NYSE: PRSP] Received an Award For $38 Million To Continue Supporting DMDC

Perspecta Inc. , reported that the company has been granted an award to keep supporting the Defense Manpower Data Center (DMDC) with a strategic...

Kazia Therapeutics [NASDAQ: KZIA] disclosed Monday that its Paxalisib has got the orphan drug designation from the US FDA. Paxalisib is formerly known as GDC-0084 for the treatment of malignant glioma.

Orphan Drug Designation is the special status awarded to the drugs which has the potential to treat rare diseases. The one benefit of ODD is that it provide the Orphan Drug Exclusivity to drug developers.

Another benefit is that it gives opportunities for grant funding, protocol assitance, and finacial benefits includes waiver of New Drug Application fees, and tax credits.

Shares of Kazia Therapeutics soared 2.47% at $7.48 during the trading of Friday. It has day low and high range of $6.86-$7.59, respectively.

In the past 52-weeks of trading, this company’s stocks fluctuated between the low of $2.27 and a high of $9.74. It has moved up 230.11% from its 52-weeks low and moved down -23.20% from its 52-weeks high.

Kazia Therapeutics has a trading volume of 797.73K and an average volume of 566.62K. Looking at its liquidity, its current ratio is 2.40. Similarly, its quick ratio is also 2.40. Furthermore, its market capitalization is 76.07 million.

Kazia disclosed that it will present its data from its ongoing phase II study of paxalisib in glioblastoma at the Society for Neuro-Oncology (SNO) Annual Meeting in November 2020.

More articles

Latest article

SG Blocks [NASDAQ: SGBX] Continues Growth Through The Execution Of 19-acre Acquisition Contract

SG Blocks, Inc. executes the contract to purchase the 19 acre Echo sites and all of its multiple structures. The company reported the...

HP Inc [NYSE: HPQ] Enters Into A Contract To Purchase HyperX

HP Inc. revealed that the company entered into a contract to purchase HyperX. It is the gaming subsidiary of Kingston Technology Company. Moreover,...

AT&T [NYSE: T] Might Sell Its Large Minority Stake At Direct TV/ U-Verse Operation To TPG

AT&T is approaching a deal to sell a significant minority stake in its DirecTV, AT&T TV Now, and U-Verse business to TPG. Additionally,...

Wipro [NYSE: WIT] Entered Into A Collaborative Agreement With Uptake

Uptake revealed that the company has collaborated with Wipro limited . The companies inked the agreement to deliver industrial intelligence for the utilities, chemical...

eXp World Holdings [NASDAQ: EXPI] Set Its Footprint In Brazil

eXp World Holdings, Inc. in order to expand its business operations has set its footprint into Brazil, under the eXp Brazil flag. Along...

L3Harris [NYSE: LHX] Grabbed A Contract Totaling Up To $137M For 4 Navigation Payload MDU

L3Harris Technologies announced that the company has grabbed a contract that totals up to $137 million for four route payload Mission Data Units...

VerifyMe [NASDAQ: VRME] Nabs Purchase Order For 2M Pre-Printed Anti-Counterfeiting Labels

VerifyMe, Inc revealed that the company has been awarded an initial purchase order for PPE anti-counterfeit technology. The company obtained a request for...

NeoGames [NASDAQ: NGMS] Announces The Go-Live Of Its Games With Austrian Lotteries

NeoGames S.A. expands further into the European lottery market by launching its first set of games. The company revealed that it signed an...